Regeneron and Sanofi to Lower Net Price of Praluent(R) (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients

Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation

Express Scripts to pass on savings to eligible patients from the participating commercial health plans

Express Scripts has selected P... Biopharmaceuticals, Reimbursement Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, PCSK9 inhibitor

Source: HSMN NewsFeed - May 1, 2018 Category: Pharmaceuticals Source Type: news